1741 related articles for article (PubMed ID: 25542804)
1. Delta-like ligand 4-targeted nanomedicine for antiangiogenic cancer therapy.
Liu YR; Guan YY; Luan X; Lu Q; Wang C; Liu HJ; Gao YG; Yang SC; Dong X; Chen HZ; Fang C
Biomaterials; 2015 Feb; 42():161-71. PubMed ID: 25542804
[TBL] [Abstract][Full Text] [Related]
2. IF7-Conjugated Nanoparticles Target Annexin 1 of Tumor Vasculature against P-gp Mediated Multidrug Resistance.
Yu DH; Liu YR; Luan X; Liu HJ; Gao YG; Wu H; Fang C; Chen HZ
Bioconjug Chem; 2015 Aug; 26(8):1702-12. PubMed ID: 26076081
[TBL] [Abstract][Full Text] [Related]
3. Selective eradication of tumor vascular pericytes by peptide-conjugated nanoparticles for antiangiogenic therapy of melanoma lung metastasis.
Guan YY; Luan X; Xu JR; Liu YR; Lu Q; Wang C; Liu HJ; Gao YG; Chen HZ; Fang C
Biomaterials; 2014 Mar; 35(9):3060-70. PubMed ID: 24393268
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle-mediated drug delivery to tumor neovasculature to combat P-gp expressing multidrug resistant cancer.
Bai F; Wang C; Lu Q; Zhao M; Ban FQ; Yu DH; Guan YY; Luan X; Liu YR; Chen HZ; Fang C
Biomaterials; 2013 Aug; 34(26):6163-74. PubMed ID: 23706689
[TBL] [Abstract][Full Text] [Related]
5. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature.
Yu DH; Lu Q; Xie J; Fang C; Chen HZ
Biomaterials; 2010 Mar; 31(8):2278-92. PubMed ID: 20053444
[TBL] [Abstract][Full Text] [Related]
6. PEG-PLA nanoparticles modified with APTEDB peptide for enhanced anti-angiogenic and anti-glioma therapy.
Gu G; Hu Q; Feng X; Gao X; Menglin J; Kang T; Jiang D; Song Q; Chen H; Chen J
Biomaterials; 2014 Sep; 35(28):8215-26. PubMed ID: 24974009
[TBL] [Abstract][Full Text] [Related]
7. CGKRK-modified nanoparticles for dual-targeting drug delivery to tumor cells and angiogenic blood vessels.
Hu Q; Gao X; Kang T; Feng X; Jiang D; Tu Y; Song Q; Yao L; Jiang X; Chen H; Chen J
Biomaterials; 2013 Dec; 34(37):9496-508. PubMed ID: 24054848
[TBL] [Abstract][Full Text] [Related]
8. Suppression of colorectal cancer subcutaneous xenograft and experimental lung metastasis using nanoparticle-mediated drug delivery to tumor neovasculature.
Wang C; Zhao M; Liu YR; Luan X; Guan YY; Lu Q; Yu DH; Bai F; Chen HZ; Fang C
Biomaterials; 2014 Jan; 35(4):1215-26. PubMed ID: 24231414
[TBL] [Abstract][Full Text] [Related]
9. iNGR-modified PEG-PLGA nanoparticles that recognize tumor vasculature and penetrate gliomas.
Kang T; Gao X; Hu Q; Jiang D; Feng X; Zhang X; Song Q; Yao L; Huang M; Jiang X; Pang Z; Chen H; Chen J
Biomaterials; 2014 May; 35(14):4319-32. PubMed ID: 24565520
[TBL] [Abstract][Full Text] [Related]
10. The use of nanoparticulate delivery systems in metronomic chemotherapy.
Yu DH; Ban FQ; Zhao M; Lu Q; Lovell JF; Bai F; Wang C; Guan YY; Luan X; Liu YR; Fang C; Chen HZ
Biomaterials; 2013 May; 34(16):3925-3937. PubMed ID: 23465835
[TBL] [Abstract][Full Text] [Related]
11. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
[TBL] [Abstract][Full Text] [Related]
12. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
[TBL] [Abstract][Full Text] [Related]
13. Self-aggregated pegylated poly (trimethylene carbonate) nanoparticles decorated with c(RGDyK) peptide for targeted paclitaxel delivery to integrin-rich tumors.
Jiang X; Sha X; Xin H; Chen L; Gao X; Wang X; Law K; Gu J; Chen Y; Jiang Y; Ren X; Ren Q; Fang X
Biomaterials; 2011 Dec; 32(35):9457-69. PubMed ID: 21911250
[TBL] [Abstract][Full Text] [Related]
14. Dual-function synthetic peptide derived from BMP4 for highly efficient tumor targeting and antiangiogenesis.
Choi SH; Lee JY; Suh JS; Park YS; Chung CP; Park YJ
Int J Nanomedicine; 2016; 11():4643-4656. PubMed ID: 27695323
[TBL] [Abstract][Full Text] [Related]
15. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects.
Maffucci T; Piccolo E; Cumashi A; Iezzi M; Riley AM; Saiardi A; Godage HY; Rossi C; Broggini M; Iacobelli S; Potter BV; Innocenti P; Falasca M
Cancer Res; 2005 Sep; 65(18):8339-49. PubMed ID: 16166311
[TBL] [Abstract][Full Text] [Related]
17. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
Xu Z; Wang Z; Jia X; Wang L; Chen Z; Wang S; Wang M; Zhang J; Wu M
Cancer Lett; 2016 Mar; 372(1):118-27. PubMed ID: 26739060
[TBL] [Abstract][Full Text] [Related]
18. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
19. Platycodin D inhibits tumor growth by antiangiogenic activity via blocking VEGFR2-mediated signaling pathway.
Luan X; Gao YG; Guan YY; Xu JR; Lu Q; Zhao M; Liu YR; Liu HJ; Fang C; Chen HZ
Toxicol Appl Pharmacol; 2014 Nov; 281(1):118-24. PubMed ID: 25250884
[TBL] [Abstract][Full Text] [Related]
20. FP3: a novel VEGF blocker with anti-angiogenic and anti-tumor effects.
Gao W; Jin K; Lan H; Han N; Cao F; Teng L
Hepatogastroenterology; 2012; 59(120):2543-7. PubMed ID: 22534543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]